Patents by Inventor Keith L. Spencer
Keith L. Spencer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8853216Abstract: The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: January 9, 2009Date of Patent: October 7, 2014Assignees: Array BioPharma, Inc., Genentech, Inc.Inventors: Josef Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang, James Graham
-
Patent number: 8846683Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: January 29, 2013Date of Patent: September 30, 2014Assignees: Array BioPharma, Inc., Genentech, Inc.Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Jun Liang, Brian S. Safina
-
Publication number: 20140148436Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Applicant: Array BioPharma, Inc.Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicolas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
-
Patent number: 8680114Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: September 25, 2009Date of Patent: March 25, 2014Assignees: Array Biopharma, Inc., Genentech, Inc.Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P. A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
-
Publication number: 20140080829Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: November 21, 2013Publication date: March 20, 2014Applicants: Genentech, Inc., Array BioPharma Inc.Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
-
Patent number: 8618097Abstract: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: July 3, 2008Date of Patent: December 31, 2013Assignees: Array Biopharma, Inc., Genentech, Inc.Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
-
Patent number: 8377937Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: GrantFiled: July 3, 2008Date of Patent: February 19, 2013Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Jun Liang, Brian S. Safina
-
Publication number: 20110160221Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: July 3, 2008Publication date: June 30, 2011Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Jun Liang, Brian S. Safina
-
Publication number: 20110015204Abstract: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: July 3, 2008Publication date: January 20, 2011Applicants: Array BioPharma, Inc., Genentech, Inc.Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
-
Publication number: 20100292244Abstract: The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: January 9, 2009Publication date: November 18, 2010Applicant: Array BioPharma Inc.Inventors: Josef Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mtchell, Keith L. Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang
-
Publication number: 20100168123Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: September 25, 2009Publication date: July 1, 2010Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
-
Patent number: 7622592Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.Type: GrantFiled: October 28, 2003Date of Patent: November 24, 2009Assignee: Merck & Co., Inc.Inventors: Yuntae Kim, Barbara Hanney, Mark E. Duggan, Keith L. Spencer
-
Publication number: 20090149467Abstract: The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.Type: ApplicationFiled: September 11, 2006Publication date: June 11, 2009Applicant: MERCK & CO., INC.Inventors: Christopher J. Dinsmore, David J. Guerin, Barbara Hanney, Yuntae Kim, Keith L. Spencer, Maricel Torrent
-
Patent number: 7186723Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: August 26, 2002Date of Patent: March 6, 2007Assignee: Merck & Co., Inc.Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
-
Patent number: 7101884Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: September 10, 2002Date of Patent: September 5, 2006Assignee: Merck & Co., Inc.Inventors: Kenneth L. Arrington, Mark E. Fraley, Barbara Hanney, Yuntae Kim, Keith L. Spencer
-
Patent number: 6927293Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: August 26, 2002Date of Patent: August 9, 2005Assignee: Merck & Co., Inc.Inventors: Yuntae Kim, Barbara Hanney, Keith L. Spencer, George D. Hartman, Kenneth L. Arrington
-
Publication number: 20040235826Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: February 24, 2004Publication date: November 25, 2004Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
-
Publication number: 20040192725Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: February 24, 2004Publication date: September 30, 2004Inventors: Yuntae Kim, Barbara Hanney, Keith L. Spencer, George D. Hartman, Kenneth L. Arrington
-
Patent number: 5042586Abstract: An articulated tractor has left and right laterally spaced apart, fore-and-aft extending side frame members which are rigidly attached between front and rear drawbar supports. The tractor also includes left and right draft links, each draft link having a front end coupled to a corresponding one of the side frame members and a rear end for coupling to an implement. A draft force sensing mechanism includes a displacement transducer mounted on one of the side frame members. A lever is pivotally mounted near the transducer and carries a plunger or shaft which operatively engages the transducer. A rod has a first end fixed to the other side frame member and a second end coupled to the lever so that changes in draft force cause deflection of the side frame members and movement of the lever relative to the transducer. The transducer responds by generating a signal representing the draft force. Movement of the rod is amplified by the lever.Type: GrantFiled: December 14, 1990Date of Patent: August 27, 1991Assignee: Deere & CompanyInventors: Keith L. Spencer, Dennis A. Bowman